MIDATECH LTD

Their core work

Midatech is a Cardiff-based biotech SME specializing in nanoparticle-based drug delivery, with particular expertise in functionalizing nanoparticle surfaces with sugars and glycans to achieve targeted biological uptake. Their industrial contribution spans both the science of how nanoparticles behave in biological environments and the hard engineering problem of manufacturing them at clinical scale under reproducible conditions. In NANOFACTURING they worked on scalable production platforms for clinically-relevant nanoparticles; in NanoCarb they moved into glyco-nanoparticle design for advanced nanomedicine applications. They operate at the interface between academic nanoscience and pharmaceutical development, bringing SME manufacturing realism to research consortia.

What they specialise in

How they've shifted over time

In their earliest H2020 work (NANOFACTURING, 2015–2019), Midatech's contribution centered on the manufacturing challenge: how to produce nanoparticles reliably and at scale for clinical settings — a process engineering problem. By the NanoCarb phase (2018–2023), the emphasis had shifted to surface chemistry: sugars, glycans, carbohydrates, and the biological interactions they enable, including protein corona formation. This trajectory suggests Midatech moved from "how do we make nanoparticles at scale" toward "how do we make nanoparticles that behave predictably inside the body" — a natural maturation for a company pushing its platform closer to therapeutic application.

Midatech is moving deeper into biologically-targeted nanomedicine, suggesting future collaboration opportunities in drug delivery, oncology targeting, or carbohydrate-based diagnostic systems rather than pure manufacturing.

How they like to work

Midatech participates exclusively as a consortium partner — they have never coordinated an H2020 project — which positions them as a specialist contributor rather than a project driver. With 23 unique partners across 10 countries from just two projects, they work in genuinely large, multi-national consortia, implying they are comfortable operating within complex governance structures. This profile is typical of an SME that brings a proprietary technology platform to academic-led research, rather than one that builds and manages research networks itself.

Midatech has connected with 23 distinct partners across 10 countries through only two projects — an unusually broad network for such a small H2020 footprint, pointing to large pan-European consortia. No geographic concentration is evident from the available data.

What sets them apart

Midatech occupies a rare position as a commercial SME with a proprietary glyco-nanoparticle platform that has demonstrably participated in both manufacturing-scale and fundamental-research EU projects — giving them credibility on both the science and the industrialization side. For consortium builders, this means Midatech can contribute not just bench knowledge but also the commercially-grounded perspective on whether a nanoparticle concept is actually manufacturable. Their sugar-based surface functionalization expertise is a defined niche, not a generic "nanomaterials" claim.

Highlights from their portfolio

• NANOFACTURING
  The largest funded project for Midatech (€866,959 EC contribution) and the one most directly aligned with their commercial mission — developing scalable, sustainable manufacturing for clinically-relevant nanoparticles.
• NanoCarb
  Represents Midatech's move into glyco-nanoparticle science under an MSCA-ITN training network, combining drug delivery research with carbohydrate chemistry — an unusual cross-disciplinary combination that signals their differentiated surface-functionalization expertise.